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Defects in DNA repair can cause various genetic diseases with severe pathological pheno-
types. Fanconi anemia (FA) is a rare disease characterized by bone marrow failure, devel-
opmental abnormalities, and increased cancer risk that is caused by defective repair of DNA
interstrand crosslinks (ICLs). Here, we identify the deubiquitylating enzyme USP48 as syn-
thetic viable for FA-gene deﬁciencies by performing genome-wide loss-of-function screens
across a panel of human haploid isogenic FA-defective cells (FANCA, FANCC, FANCG,
FANCI, FANCD2). Thus, as compared to FA-defective cells alone, FA-deﬁcient cells addi-
tionally lacking USP48 are less sensitive to genotoxic stress induced by ICL agents and
display enhanced, BRCA1-dependent, clearance of DNA damage. Consequently, USP48
inactivation reduces chromosomal instability of FA-defective cells. Our results highlight a role
for USP48 in controlling DNA repair and suggest it as a potential target that could be
therapeutically exploited for FA.
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The human genome is constantly exposed to various sourcesof DNA damage that can arise from either endogenous orexogenous sources. To deal with this stress, cells possess
several highly conserved and effective mechanisms for DNA
repair. If these repair mechanisms are defective, due to germline
mutations in relevant DNA repair genes, rare diseases with DNA
repair deﬁciencies can arise1,2. One such disease is Fanconi
anemia (FA), which is characterized by chromosomal instability,
bone marrow failure, and cancer predisposition, for which
inadequate treatments are currently available3,4. FA is caused by
mutations in genes encoding components of the FA pathway,
which mediates repair of DNA interstrand crosslinks (ICLs),
highly toxic lesions that block DNA replication and transcription.
Consequently, cells that have disruptive mutations in FA genes
exhibit increased sensitivity to DNA ICL-inducing agents3,4.
The classical concept of synthetic viability (also termed syn-
thetic rescue or genetic suppression), in combination with the use
of advanced and high-throughput methods allows for the devel-
opment of new approaches to ameliorate defects associated with
human genetic diseases5–9. Moreover, the identiﬁcation of such
interactions provides signiﬁcant insights into the mechanisms
underlying molecular processes and crosstalk between cellular
pathways. To explore, in an unbiased and systematic manner,
genetic synthetic-viable interactions for FA deﬁciency, we have
used human haploid genetic screens—a powerful approach that
can identify genetic interactions in human cells10–12. Thus, we
have used a previously described gene-trap retrovirus10 to
mutagenize a panel of human cell lines individually carrying
mutations in ﬁve different FA genes (FANCA, FANCC, FANCG,
FANCI, and FANCD2). As described herein, through this
approach, we identify USP48 as a deubiquitylating enzyme
(DUB) whose loss alleviates increased sensitivity and genomic
instability of FA-deﬁcient cells following DNA crosslinking
damage, while enhancing the recruitment of homologous
recombination (HR) markers and histone H2A ubiquitylation.
Results
Map of synthetic rescue interactions in FA cells. In order to
mimic the defect observed in FA in a cellular system that is
appropriate for further genetic manipulations, we generated
CRISPR-Cas9-mediated knockout HAP1 cells with individual
mutations in ﬁve FA genes: FANCA, FANCC, FANCG, FANCI,
and FANCD2. We selected these genes based on their clinical
relevance (FANCA, FANCC, and FANCG account for the
majority of mutations in FA patients) but also based on their
molecular function, as FANCA, FANCC, and FANCG are part of
the core complex, while FANCI and FANCD2 function down-
stream during ICL repair, in order to broadly cover the FA
pathway3,4. The HAP1 cell line is near-haploid, making it ideal
for genetic screens using insertion mutagenesis, since disruptive
mutations in a single allele will result in a knockout10. We con-
ﬁrmed the generation of frameshift mutations and loss of protein
expression in the knockout cell lines by Sanger sequencing and
immunoblotting (Supplementary Fig. 1a, b). In line with a pre-
vious report, we noted that loss of FANCA affected the protein
stability of FANCG and vice-versa13. We also observed mutual
interdependences for FANCI and FANCD2 protein stabilities.
The expected hypersensitivity of the FA knockout cells to the
DNA crosslinking agent mitomycin C (MMC) was conﬁrmed by
cell viability assays (Fig. 1a) and clonogenic survival assays
(Supplementary Fig. 1c).
To screen for potential genetic disruptions that alleviate the
DNA damage hypersensitivity of FA-defective cells, we inserted,
via retroviral delivery, a gene-trap cassette that contains a splice
acceptor site into the HAP1 knockout cells. This method has been
previously used successfully in haploid genetic screens10–12. We
next treated the mutagenized cells with MMC at a dose that we
predetermined as selectively killing the FA-deﬁcient cells, thereby
providing a selective pressure to enrich for resistant cells (Fig. 1b).
Genomic DNA was then extracted and subjected to next
generation sequencing (NGS), allowing for the mapping of both
the position and orientation of the gene-trap cassette. As a
control, we additionally analyzed a non-selected, untreated
mutagenized population of wild-type (WT) HAP1 cells14.
In order to identify cellular processes and pathways represented
by the genes that speciﬁcally rescue FA-defective cells but not
WT cells, we overlaid the signiﬁcantly enriched hits onto a
manually curated interactome network of physical protein–protein
interactions15. We identiﬁed neighboring genes to this initial set
using network propagation based on a previously described
method16. Groups of highly interconnected genes were revealed
using a modularity maximization clustering algorithm17, which
after functional enrichment analysis of each cluster, showed
signiﬁcant enrichment for biologically-relevant canonical path-
ways (Fig. 1c; Supplementary Data 1). Clusters including
“Ubiquitin-mediated proteolysis” and “Pathways in cancer”
demonstrate the high connectivity among the identiﬁed genes.
Also displayed are the DNA repair genes that were not identiﬁed
tightly connected in a cluster but rather falling within the above
two mentioned clusters (Fig. 1c; Supplementary Data 1).
USP48 loss alleviates sensitivity of FA cells to ICLs. We next
created a synthetic-viable interaction network from all the iden-
tiﬁed rescue protein-coding genes (Fig. 2a; Supplementary
Data 2). Closer examination of the top 10 individual genes
revealed NQO1 and USP48 as the most recurrently targeted and
signiﬁcantly enriched genes, based on fdr-corrected p-values (q-
values) (Fig. 2b). We, therefore, chose to focus on these for our
ensuing analyses. Other enriched genes, notably LAMTOR1 and
LAMTOR5, which are members of the LAMTOR complex and
promote activation of the mTOR signaling pathway, will be the
subject of our ensuing studies. In addition, we note that we have
recently reported that inactivation of members of the BLM
complex (BLM, TOP3A, and RMI1), which appear among the top
shared hits among FA-deﬁcient cell screens, can rescue the sur-
vival of FA-deﬁcient cells in response to ICL induction18.
NQO1 is a quinone reductase that has been shown to
contribute to MMC bio-activation in cells, thereby allowing its
toxic actions19. Furthermore, expression levels of NQO1 in
human tumors have been positively correlated to enhanced
sensitivity to MMC treatment20. As expected from its function in
MMC activation, disruptive insertions within NQO1 were highly
signiﬁcantly enriched in wild-type (WT) cells as well as FA-
deﬁcient cells selected for MMC resistance, indicating a general
mode-of-action irrespective of the DNA repair status of the cell
line.
More interestingly, mutagenic insertions within USP48, a
deubiquitylating enzyme (DUB), were found as signiﬁcantly
enriched in resistant populations of all the FA-deﬁcient back-
grounds but not in WT cells, potentially indicating a function
speciﬁcally connected to the DNA repair defect in FA cells.
Moreover, mapping of the insertion sites of the gene-trap cassette
in USP48 showed that the majority of insertions were localized
upstream in the gene or at a region corresponding to the catalytic
domain of USP48 (Supplementary Fig. 2a), indicative of
disruptive mutations resulting in loss of function. We next
validated this rescue interaction by generating, via de novo
CRISPR-Cas9 gene editing, a HAP1 cell line double mutant for
FANCC and USP48 (Fig. 3a and Supplementary Fig. 2b). The
resulting double mutant, ΔUSP48 ΔFANCC, was more resistant to
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crosslinking agents compared to the ΔFANCC single mutant, as
shown by clonogenic survival after treatment with MMC,
cisplatin or diepoxybutane (DEB) (Fig. 3b–d). Interestingly, we
did not observe the same effect on survival when we compared
WT cells to ΔUSP48 cells, although a slight but not signiﬁcant
difference was observed, further validating the results of our
screens and the speciﬁcity of this genetic interaction for FA-
deﬁcient cells. Re-introduction of exogenous wild-type USP48,
but not the catalytically inactive C98S USP48 mutant, partially
reduced ICL resistance of ΔUSP48ΔFANCC cells (Supplementary
Fig. 2c, d), thus indicating that lack of USP48 catalytic activity is
important for the increased survival of ΔUSP48ΔFANCC cells.
Further conﬁrming that the synthetic rescue was indeed
dependent on USP48, when we subjected USP48 to short-
hairpin RNA (shRNA) depletion (Supplementary Fig. 2e, f) or
carried out USP48 gene inactivation by CRISPR-Cas9 editing by
using a different single guide (sg)RNA targeting a different exon
(Supplementary Fig. 2g, h) in ΔFANCC cells, we observed similar
results. We also tested the effect of USP48 loss on MMC
sensitivity of ΔFANCG and ΔFANCD2 cells using CRISPR-Cas9
editing to target USP48. The pooled populations of FA mutant
cells targeted for USP48 displayed reduced USP48 protein
(Supplementary Fig. 2g) and increased survival to MMC
(Supplementary Fig. 2h), thus conﬁrming the synthetic viability
interaction in additional FA backgrounds.
Since monoubiquitylation of components of the FANCI/
FANCD2 complex is an important step of ICL repair3,4 and
considering that USP48 is a DUB, we tested whether USP48
depletion could rescue the FANCI/FANCD2 monoubiquitylation
defect of ΔFANCC cells. Western immunoblot assays revealed that
lack of MMC-induced FANCI/FANCD2 monoubiquitylation in
ΔFANCC cells was not restored upon shRNA-mediated depletion
of USP48 (Supplementary Fig. 2i), suggesting that USP48 may
affect the repair of ICLs downstream of FANCI/FANCD2.
Moreover, USP48 depletion in ΔFANCC cells did not correct
the defect that these cells had in recruiting FANCD2 to MMC-
induced DNA-damage foci, thereby implying that the mechanism
of rescue was independent of FANCD2 (Supplementary Fig. 2j).
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Fig. 1 Genetic screens identify synthetic-viable interactions for FA. a Dose–response of FA-defective HAP1 cell lines to MMC exposure. Cells were treated
for 3 days and viability was measured by Cell Titer Glo®. Error bars indicate S.E.M (standard error of the mean) of triplicates. b Workﬂow for the
identiﬁcation of genetic synthetic-viable interactions for FA-defective human haploid HAP1 cells following MMC exposure by gene-trap-based insertional
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Fig. 2 Synthetic-viable genes for FA cells. aMap of the synthetic viability interaction network identiﬁed by insertional mutagenesis screens using wild-type
(WT) and ﬁve FA-deﬁcient HAP1 cell lines after MMC treatment. Links in this network indicate an increased viability of cell lines with a given mutational
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USP48 is recruited to sites of DNA damage. In light of our
ﬁndings, we next investigated the cellular localization of USP48
and whether it is recruited to sites of DNA damage. GFP-tagged
USP48 was expressed in WT and ΔFANCC cells with and without
MMC treatment. We observed that GFP-USP48, both WT and
the catalytically inactive C98S mutant, localized primarily in the
nucleus with a pan-nuclear signal (Supplementary Fig. 3). Inter-
estingly, the catalytically inactive C98S mutant, but not WT
USP48, formed foci that co-localized with γH2AX foci (arrows in
Supplementary Fig. 3). This suggested that USP48 interacts with a
substrate at the site of damage and inhibition of its activity
entraps the enzyme, hence leading to the formation of USP48
foci. We next tested if USP48 is speciﬁcally recruited to sites of
DNA damage created by laser micro-irradiation of FANCC-
proﬁcient (U2OS) and FANCC-deﬁcient (VU1131) cells
(Supplementary Fig. 4a). Indeed, both WT and C98S USP48
accumulated at sites of laser micro-irradiation within 10 min of
DNA-damage induction (then declined after a further 10 min),
with the mutant protein accumulating more strongly than the
WT protein (Supplementary Fig. 4b, c), again suggesting that
mutation of the catalytic domain may prevent release of USP48
from its substrate(s) at DNA-damage sites. Furthermore, we
found that USP48 DNA-damage accumulation was more efﬁcient
in FANCC-deﬁcient cells than in these cells complemented with
FANCC, suggesting that USP48 recruitment may be actively
suppressed by FANCC and associated FA proteins (Supplemen-
tary Fig. 4d, e). Finally, we tested whether USP48 can speciﬁcally
localize to ICLs by irradiating cells that had been pre-treated with
Trioxalen, a psoralen derivative that forms ICLs upon UV
irradiation (Fig. 4a). Notably, we observed efﬁcient recruitment of
mutant USP48 in ICL-containing tracks marked by FANCD2 in a
substantial fraction of cells, while we were unable to detect WT
USP48 recruitment (Fig. 4b). By contrast, we detected DNA-
damage accumulation of both WT and mutant USP48 in a sub-
stantial fraction of FANCC-deﬁcient cells, with the mutant
protein being detectable in laser tracks in a much larger pro-
portion of the cells than the WT protein (Fig. 4b). Collectively,
these data indicated that USP48 is recruited to ICLs and that it
appears to do so independently of a functional FA-protein
assembly.
USP48 loss promotes repair of MMC-induced damage in FA
cells. We next determined whether the effect of USP48 loss on
survival of FA-defective cells after treatment with DNA cross-
linking agents correlated with less DNA damage induction and/or
increased DNA repair. Hence, we analyzed the formation and
clearance of γH2AX foci, a marker for DNA damage lesions, in
WT, ΔUSP48, ΔFANCC, and ΔUSP48ΔFANCC cells at different
time-points after being treated with MMC for 18 h. Although the
number of γH2AX foci were similar in all settings immediately
after MMC treatment (0 h after MMC removal), we observed
persistence of γH2AX foci at 48 h after MMC removal in
ΔFANCC cells but not in ΔUSP48ΔFANCC cells (Fig. 4c, d).
These ﬁndings thus suggested that ΔUSP48ΔFANCC cells repair
MMC-induced DNA damage more efﬁciently than ΔFANCC
cells. Interestingly, we also observed that ΔUSP48 cells displayed
increased clearance of γH2AX foci than WT cells (Fig. 4c, d),
suggesting that loss of USP48 improves DNA repair also in ICL-
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repair proﬁcient cells, although with a less pronounced pheno-
typic effect than in a ΔFANCC setting.
USP48 loss enhances BRCA1 and RAD51 localization in FA
cells. FA-protein-dependent homologous recombination (HR)
plays a crucial role in the repair of ICL lesions during S-phase21.
To assess the potential impact of USP48 loss on HR in ΔFANCC
cells, we examined the DNA damage-induced recruitment of
BRCA1, a HR factor22. Analysis of BRCA1 localization into foci
at DNA damage sites revealed that ΔUSP48ΔFANCC cells dis-
played signiﬁcantly higher numbers of BRCA1 foci at 24 and 48 h
after MMC treatment as compared to ΔFANCC cells (Fig. 5a, b).
Furthermore, ΔUSP48ΔFANCC cells displayed a higher number
of BRCA1 foci in untreated conditions, which could reﬂect
enhanced BRCA1 recruitment following endogenous replication
stress23. We did not, however, observe signiﬁcant differences in
the formation or persistence of BRCA1 foci between WT and
ΔUSP48 cells (Fig. 5a, b). Since we had found that USP48 can
affect the formation or maintenance of BRCA1 foci in ΔFANCC
cells, we then addressed whether it also co-localizes with BRCA1
at DNA damage sites. To this end, we investigated the co-
localization of BRCA1 with GFP-tagged WT or C98S USP48,
after MMC treatment of ΔUSP48ΔFANCC cells. In accord with
our results on its co-localization with γ-H2AX (Supplementary
Fig. 3), mutant USP48 was observed to co-localize with nuclear
foci of BRCA1 (Fig. 5c). Interestingly, in many cases co-
localization was not exact with adjacent foci being observed,
possibly suggesting competitive activities of the two proteins in
DNA repair pathway choice.
BRCA1 is required for loading of RAD51, a protein necessary
for pairing of homologous regions and strand exchange during
HR22,24. We thus measured, by immunoﬂuorescence staining,
DNA damage recruitment of RAD51. At 18 h after MMC
treatment, recruitment of RAD51 into foci was signiﬁcantly
higher in U2OS cells simultaneously depleted for both FANCC
and USP48 by siRNA treatment, compared to cells depleted for
FANCC alone (Fig. 5d and Supplementary Fig. 5a–c), implying
that USP48 loss restores HR efﬁciency at replication forks
encountering ICL damage in FA-deﬁcient cells. By contrast,
USP48 depletion did not enhance MMC-induced RAD51 focus
formation in control cells (Fig. 5d and Supplementary Fig. 5c),
suggesting that USP48 may inhibit HR processes speciﬁcally in an
FA-deﬁcient background. Altogether, these ﬁndings suggested
that USP48 counteracts BRCA1 and RAD51 recruitment at sites
of ICLs, most notably when the FA pathway is deﬁcient, thus
preventing efﬁcient HR.
To explore potential effects of USP48 on HR processes, we used
the well established Trafﬁc Light Reporter (TLR) system in
human U2OS cells25,26. Our results showed that depletion of
USP48 reduced HR levels in both WT and FANCC-depleted cell
backgrounds when compared to control cells (Supplementary
Fig. 5d). While this did not correlate with the increased RAD51
recruitment we observed upon USP48 depletion after induction of
DNA ICLs, we note that the direct generation of DNA double-
strand breaks by the endonuclease I-SceI in this system renders it
quite different from the HR-repair templates generated via ICL
processing in S-phase. As an alternative measurement for
homology-based repair, we assessed RPA recruitment to
chromatin as an indicator of end-resection. We did not observe
a major effect of USP48 depletion on RPA chromatinization
upon induction of camptothecin (CPT)-induced replication
stress, although a marginally signiﬁcant increase of RPA foci
was evident when both USP48 and FANCC were depleted
compared to when FANCC was depleted alone (Supplementary
Fig. 5e).
USP48 loss rescues ICL sensitivity of FA cells through BRCA1.
Since ΔUSP48ΔFANCC cells exhibited markers of enhanced ICL-
dependent HR (as evidenced by BRCA1 and RAD51 foci)
compared to ΔFANCC cells, and because USP48 inactivation
alleviated the sensitivity of ΔFANCC cells to DNA crosslinking
agents, we determined whether this effect on cell survival
depended on BRCA1. Indeed, shRNA-mediated depletion of
BRCA1 reversed the resistance of ΔUSP48ΔFANCC cells to MMC
or cisplatin, as shown by clonogenic survival assays (Fig. 6a, b,
marked by green frame), although residual resistance was still
observed when compared to BRCA1-depleted ΔFANCC cells
(Fig. 6b, marked by red frame), possibly because of incomplete
shRNA-mediated depletion resulting in residual BRCA1 activity,
or reﬂecting an additional BRCA1-independent effect of USP48.
These results were thus in line with a model in which USP48
functions, at least in part, to counteract BRCA1 activity.
To explore the potential involvement of BRCA1 ubiquitin
ligase activity27, we reconstituted BRCA1-depleted ΔUSP48Δ-
FANCC cells with wild-type BRCA1 (WT) or with a mutant form
of BRCA1 carrying a point mutation (I26A), previously shown to
affect its ubiquitin ligase activity28,29. Notably, we found that both
WT and I26A BRCA1 were able to alleviate the hypersensitivity
of BRCA1-depleted cells towards MMC treatment (Supplemen-
tary Fig. 5f, g), suggesting that the E3 ubiquitin ligase activity of
BRCA1 might not be crucial for the synthetic rescue phenotype
observed upon loss of USP48 in a FANCC-deﬁcient background.
Loss of USP48 affects histone H2A ubiquitylation. We next
asked what could be the substrate of USP48 in the context of ICL
repair. Ubiquitylation of RPA has been recently implicated in the
proper recruitment and resolution of RAD51 accumulation at
sites of DNA ICL repair, in a manner dependent on the RFWD3
ubiquitin ligase30,31. Interestingly, RFWD3-deﬁcient cells are
hypersensitive to DNA crosslinking agents, thus supporting a
model where USP48 might counteract the effect of RFWD3 on
RPA and RAD51 recruitment. However, we did not observe a
signiﬁcant impact of USP48 siRNA depletion on the levels of
ubiquitylation of GFP-tagged RPA70 in U2OS cells treated with
camptothecin (Supplementary Fig. 5h, i). Based on these ﬁndings,
we conclude that it is unlikely that USP48 counteracts RNFWD3/
RNF4/PRP19-mediated ubiquitylation of RPA70.
USP48 has been reported to be recruited on chromatin and be
associated to modiﬁed histones32. Histone ubiquitylation and
especially H2A/H2B ubiquitylation is involved in repair of DNA
double-strand breaks33,34, and various sites have been identiﬁed as
ubiquitin substrates that are ubiquitylated by different ubiquitin E3
ligases. We thus decided to investigate whether histone ubiquityla-
tion levels are affected by loss of USP48. To this end, we
immunoprecipitated Flag-tagged H2A from WT, ΔUSP48,
ΔFANCC, and ΔUSP48ΔFANCC cells following MMC treatment
and blotted for ubiquitin (Fig. 6c and Supplementary Fig. 5j).
Immunoprecipitation of Flag-tagged WT H2A, followed by
immunoblotting against protein-conjugated ubiquitin chains using
FK2 antibody showed a small but noticable increase in poly-
ubiquitylated forms of H2A in double ΔUSP48ΔFANCC cells
compared to ΔFANCC cells, and increase that was further enhanced
by MMC treatment (Fig. 6c). Immunoprecipitation of a mutant
form of H2A that lacks the ubiquitin target sites K5-9-118-119-125-
127-129 (K5-9-118-119-125-127-129R mutant) showed almost no
poly-ubiquitylation, implicating at least one of these sites as being
affected by USP48 loss (Fig. 6c, residual bands for the immuno-
precipitated mutant H2A in the ΔUSP48 ΔFANCC background
likely correspond to ubiquitylated H2A at RNF168-dependent sites
K13-15, which were not targeted for mutation, thus not excluding
their contribution in the observed poly-ubiquitylated H2A proﬁle).
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These data raise the possibility that USP48 might at least in part
affect the ICL sensitivity of FANC-gene deﬁcient via inﬂuencing
H2A ubiquitylation.
Genomic instability of FA cells is reduced upon USP48 loss. A
hallmark of FA-defective cells is increased chromosomal aberra-
tions upon treatment with crosslinking agents3,4, manifested as
breaks and radials on mitotic chromosomes. As we had found
that USP48 loss enhances HR in ΔFANCC cells, we determined
whether it could also alleviate chromosome breaks in ΔFANCC
cells. Indeed, analysis of metaphase spreads from cells treated
with MMC showed that chromosomal aberrations were sig-
niﬁcantly reduced in ΔUSP48ΔFANCC cells compared to
ΔFANCC cells, the latter of which exhibited a high number of
breaks after MMC treatment compared to WT cells (Fig. 6d;
representative images of chromosomal aberrations shown in
Fig. 6e). This result thus indicated that absence of USP48 can
alleviate the increased genomic instability of FA-defective cells.
Discussion
In the current study, we have taken an unbiased approach to
reveal an extended network of synthetic rescue interactions for
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FA deﬁciency, providing a resource for potential therapeutic
targets. Among these, we have selected and validated a synthetic-
viable interaction between the deubiquitylating enzyme USP48
and FA genes. We have shown that USP48 loss speciﬁcally
improves the survival of FA-defective cells to DNA crosslinking
agents, and that this is associated with enhanced recruitment of
the HR proteins BRCA1 and RAD51 to DNA damage sites and
reduced chromosomal instability. This implies that USP48
counteracts BRCA1 activity or indirectly prevents conditions
permissive for HR.
Our data indicate an early role for USP48 at sites of DNA
damage, as shown by its rapid recruitment at irradiated sites,
likely targeting substrates at or ﬂanking sites of DNA lesions.
Interestingly, we have found that recruitment and retention of
USP48 at ICLs appears to be negatively modulated by its catalytic
activity and by the presence of FA proteins, suggesting that FA-
protein assembly at DNA damage sites serves to likely counteract
USP48 recruitment and activity at sites of DNA ICLs to promote
HR and genome integrity. Our ﬁndings thus support a role for
USP48 in regulating the balance between different repair path-
ways at the site of damage.
While our manuscript was under review, a new study was
published showing that USP48 is recruited to sites of double-
strand breaks and that its depletion leads to increased RAD51
recruitment and enhanced BRCA1-mediated DNA end-
resection35. Although not in the context of interstrand crosslink
repair, these results are complementary and similar to what we
observed, and further highlight that USP48 plays a role(s) in
DNA repair. Notably, the authors in this study showed the
activity of USP48 counteracts BRCA1-mediated ubquitylation of
H2A K127/129 and thereby preventing chromatin remodeling
and resection during double-strand break repair after IR and
camptothecin treatment35. Signiﬁcantly, however, our studies in
USP48-depleted FA-gene-deﬁcient cells have indicated that both
wild-type and I26A BRCA1 were able to alleviate the hypersen-
sitivity of BRCA1-depleted FA-gene deﬁcient, USP48-depleted
cells towards MMC treatment. This suggests that the effect of
BRCA1 under this setting is unlikely to operate via effects on
reversing BRCA1-mediated ubiquitylation of histone H2A or
other proteins. However, since the role of E3 ubiquitin ligase
activity of BRCA1 is a subject of debate28,29,36, more experiments
are needed to better understand its involvement or not in the
mechanism of the genetic interaction between USP48 and FA
genes during crosslink repair. It is important to note that our data
do not exclude the contribution of other H2A sites in the
mechanism by which USP48 loss counteracts the ICL hypersen-
sitivity of FA cells. Since crosstalk between histone marks has also
been reported37, another possible mechanism is that USP48
regulates ubiquitylation of multiple H2A sites by trimming poly-
ubiquitin chains, thus performing a balancing act between dif-
ferent DNA repair pathways in combination with the activity of
E3 ubiquitin ligases such as RNF168 or others.
An important step in ICL repair is unhooking of the DNA
lesion, which happens with the contribution of various nucleases,
including FAN1, MUS81-EME1, XPF-ERCC1, SLX1, and the
scaffold protein SLX4, all thought to assemble into a large
structure-speciﬁc endonuclease complex21. Importantly, SLX4
and FAN1 both contain UBZ domains that recognize ubiquitin
and play important roles in their recruitment and function that is
also dependent, at least partially, on FA proteins, especially
monoubiquitylated FANCD2/FANCI38–41. Our data demonstrate
that loss of USP48 does not restore FANCI/FANCD2 mono-
ubiquitylation or FANCD2 recruitment at ICLs, but if USP48
targets one or more sites on H2A that can be recognized by these
nucleases, then loss of USP48 might bypass the requirement of
the FA proteins and allow the recruitment of FAN1 or SLX4 and
subsequent unhooking of the ICL in an FA-deﬁcient background.
Recently, USP48 has also been shown to promote the stability
of Mdm2 that in turn results in enhanced degradation of p5342,
which has been associated to FA cell death43. However,
HAP1 cells, which have used in various parts of our study, have a
p53 mutation, which likely affects p53 normal function, as we
have shown in a previous study18 but also as implied by the fact
that p53 is not retrieved as a signiﬁcant suppressor-hit from any
of our screens. Moreover, we have shown similar effects upon
USP48 depletion in U2OS cells, which possess wild-type p53. We
thus, conclude that the function of USP48 in the context of ICL
repair and synthetic rescue in an FA-deﬁcient background is
unlikely to be through its effects on p53.
Importantly, the results of the present study show that loss of
USP48 improves DNA repair and prevents genomic instability of
FA-defective cells, thus highlighting the potential of developing
USP48 inhibitory molecules as novel therapeutic approaches that
could potentially alleviate the phenotypes of FA patients. In this
regard, it will be of interest to employ existing FA mouse models
to investigate whether loss or inhibition of USP48 could alleviate
disease phenotypes.
Methods
Cell lines and culture conditions. Human HAP1 cells were obtained from Hor-
izon Discovery, they were grown in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM)
from GIBCO®, containing L-Glutamine and 25 mM HEPES and supplemented with
10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (P/S).
HEK293T cells were obtained from the CRUK Cell Facility, they were used for
virus production, expanded in Dulbecco’s modiﬁed Eagle medium (DMEM) and
supplemented with 10% FBS. U2OS cells were originally obtained from ATCC cell
repository, they were cultured in DMEM (Sigma-Aldrich), supplemented with 10%
FBS. Human mCherry-Geminin-expressing U2OS44, FANCC-deﬁcient VU1131
and complemented VU1131 cells (a gift from Josephine Dorsman, VU Medical
Center Amsterdam) were cultured in DMEM, supplemented with antibiotics and
10% fetal calf serum. VU1131 cells were grown with G418 (300 μg/mL). All cells
were grown at 37 °C in a 3% oxygen and 5% CO2 atmosphere. All cell lines used in
this publication were tested negative for mycoplasma contamination using the
MycoAlert™ Mycoplasma Detection Kit. They were all authenticated by the spe-
ciﬁed providers and, furthermore, they are not listed as commonly misidentiﬁed by
ICLAC.
CRISPR-Cas9-mediated gene editing. ΔUSP48 HAP1 cells were purchased from
Horizon Genomics (clone HZGHC000915c012). CRISPR-Cas9 knockouts of
FANCA, FANCC, FANCG, and FANCI were generated in collaboration with
Horizon Genomics. Sequences for gRNAs were designed by Horizon Genomics or
with the use of http://crispr.mit.edu/ and https://www.deskgen.com/landing/,
respectively. Sequences of gRNAs used were:
FANCA: 5'-CGGGATGGTTGCCTCTAGCG-3';
FANCC: 5'-GCCAACAGTTGACCAATTGT-3';
FANCG: 5'- GAATGACCGGCTCGTTCGAC-3';
FANCI: 5'-GTATCCAGTTGGTGGAATCG-3';
USP48ex1: 5'- TCGAGACCGCTTACCGCATC-3'
USP48ex6: 5'-GCTTAGACTCTCTGCCACAC-3'
Sanger sequencing. Genomic DNA was extracted using the Qiagen Biotech
DirectPCR Lysis Reagent (Cell) according to the manufacture’s protocol. Genomic
regions around the gRNA-targeted sequences were ampliﬁed using the following
primer pairs:
FANCA-For: 5'-ATACTGAGCAAACTCTAACAGGGAA -3';
FANCA-Rev: 5'- GGCATTTTAAACAGCAAGTCTTTGG-3';
FANCC-For: 5'-CAAACCTACACACACATACATGGAC-3';
FANCC-Rev: 5'-ACTAAACAAGAAGCATTCACGTTCC-3';
FANCG-For: 5'- GTTGTCACTGAGGATCAATCCTTTT-3';
FANCG-Rev: 5'- TTCACCCTTCCTAAGTCCGCTT-3';
FANCI-For: 5'-CTTTTTCAAAGCCCTTAACCATTGC-3';
FANCI-Rev: 5'-CCCTCAACAAATTACAAACCCTCAA-3';
USP48-For: 5'- GATGGGAACCCAAACCTTCCTAAAG-3';
USP48-Rev: 5'- CTCGGGAGGCGTTCCTGG-3'.
The following sequencing primers were used:
FANCA: 5'-GGCATTTTAAACAGCAAGTCTTTGG-3';
FANCC: 5'-ACTAAACAAGAAGCATTCACGTTCC-3';
FANCG: 5'- GTTGTCACTGAGGATCAATCCTTTT-3';
FANCI: 5'-CTTTTTCAAAGCCCTTAACCATTGC-3';
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USP48: 5'- GATGGGAACCCAAACCTTCCTAAAG-3'.
PCR ampliﬁcation conditions were as follows: heat lid 110 °C; 94 °C 2min; loop
35 × (94 °C 30 s; 55 °C 30 s; 68 °C 1 min) 68 °C 7min. Frameshift mutations were
identiﬁed using Nucleotide BLAST against the reference genome
GCF_000001405.33.
Plasmids. GFP-WT and GFP-C98S mutant USP48 constructs were generated via
Gateway cloning. WT and C98S mutant USP48 cDNA sequences were ampliﬁed by
PCR using primers complementary to attB sites and partially to cDNA sequence
and cloned into pDONR221 vector. Following reaction with L recombinase
(Invitrogen, Thermo Fisher Sci) WT and C98S mutant USP48 cDNA sequences
were cloned into the pcDNA6.2/N-EmGFP-DEST destination vector (Invitrogen,
Thermo Fisher Sci). Correct sequence and in-frame N-terminal expression of the
GFP tag was conﬁrmed by Sanger sequencing. A mammalian expression plasmid
encoding 3 × HA-Ubiquitin was previously generated together with the laboratories
of Yossi Shiloh (Sackler School of Medicine, University of Tel Aviv) and Moshe
Oren (Weizmann Institute of Science). pCDNA3.1-Flag-H2A (Addgene plasmid
# 63560) and pCDNA3.1-Flag-H2A K5-9-118-119-125-127-129R (Addgene plas-
mid # 63565) were a gift from Titia Sixma34. pEGFP1-C1-BRCA1 and pCIN4-Flag-
BARD1 plasmids were a kind gift from Jiri Lukas (Novo Nordisk Foundation
Center for Protein Research, University of Copenhagen). To generate the I26A
mutant construct, the Q5® site-directed mutagenesis kit (NEB) was used according
to the manufacturer’s instructions. The mutagenesis primers were designed using
the NEBaseChanger™ Tool (http://nebasechanger.neb.com/). The following primer
sequences were used:
BRCA1 I26A For: 5'-AGAGTGTCCCgcCTGTCTGGAG-3',
BRCA1 I26A Rev: 5'-AAGATTTTCTGCATAGCATTAATG-3'
Plasmid transfection. Transfection of pcDNA6.2/N-emGFP USP48 WT and C98S
vectors was carried out using Xfect transfection reagent (Takara, Clontech)
according to manufacturer’s protocol. Brieﬂy, HAP1 cells at 60% conﬂuency in six-
wells plates were transfected with 8 μg of plasmid in antibiotics-free medium
containing 10% FBS. The next day, cells were trypsinized and seeded for colony
formation or immunoﬂuorescence assays.
BRCA1 siRNA transfection. Transfection of HAP1 cells with siBRCA1 and non-
targeting control siRNA was done using Dharmafect-1 (Dharmacon) reagent
according to manufacturer’s instructions. For expression of BRCA1 constructs,
Effectene transfection reagent (Qiagen) was used the next day following siRNA
transfection according to manufacturer’s protocol.
siRNA sequences targeting 3'UTR of BRCA1 were synthesized by Dharmacon:
siBRCA1 3'UTR-1: GCUCCUCUCACUCUUCAGU
siBRCA1 3'UTR-2: AAGCUCCUCUCACUCUUCAGU
BRCA1 knock-down by shRNA. HAP1 cells were infected with the virus-
containing supernatant in the presence of polybrene (ﬁnal concentration 8 μg/mL),
diluted 1:3. Infected cells were selected using puromycin (2 μg/mL; Sigma-Aldrich)
for 48 h.
DsiRNAs. Pre-designed dicer-substrate short interfering 27-mer RNAs (DsiRNAs)
targeting USP48 (design ID hs.Ri.USP48.13.1 and hs.Ri.USP48.13.2), FANCC
(design ID hs.Ri.FANCC.13.1 and hs.Ri.FANCC.13.2) or RBBP8/CtiP (design ID
hs.Ri.RBBP8.13.1) were from Integrated DNA Technologies. Cells were transfected
with 5 nmol DsiRNAs using Lipofectamine RNAiMAX (Thermo Fisher Scientiﬁc)
according to the manufacturer’s instructions.
Quantitative reverse transcription PCR (RT-PCR). Cells were harvested from
which RNA was isolated using Trizol extraction (following the manufacturer's
instructions). RNA was treated with 1 μL DNase (Sigma) and then reverse tran-
scribed with the SuperScript III Reverse Transcriptase protocol (Invitrogen) to
obtain cDNA. An amount of 1 μg of cDNA template was used for the qRT-PCR
using SYBR Green qPCR Mastermix (Qiagen). Analysis was performed out in
triplicates using expression of GAPDH for normalization of data. The PCR was
performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems). The
following primers were used:
BRCA1: 5'-TCAACTCCAGACAGATGGGAC-3'; 5'-
GGCTGTGGGGTTTCTCAGAT-3', GAPDH: 5'-
CGAGCCACATCGCTCAGACA-3'; 5'-GGCGCCCAATACGACCAAAT-3'.
Dose–response curves. Dose–response curve for mitomycin C (MMC), was
performed in 96-well plates by seeding 1000 cells per well, the day before treat-
ment. The following day, compounds were added at twofold serial dilutions. Four
days after treatment with compounds, cell viability was measured using CellTiter-
Glo (Promega).
Colony formation assays. Cells were seeded in six-well plates the day before
exposure to compounds (1000 cells/well). The next day compounds were added at
the indicated concentrations. Three days after, compound-containing medium was
changed with fresh compound-free medium. Cells were left in culture until visible
colonies appeared (7–10 days). Colonies were then ﬁxed in 3.7% formaldehyde in
phosphate-buffered saline (PBS) for 1 h, washed in PBS and stained with 0.1%
crystal violet solution in PBS supplemented with 10% ethanol for 1 h, followed by
washing twice with H2O. For quantiﬁcation, crystal violet was extracted using 50%
EtOH, and absorbance was measured at 595 nm.
Laser micro-irradiation. U2OS cells were grown on 18mm coverslips and sensi-
tized with 6 μM Trioxalen for 1 h, or 10 μM 5′-bromo-2-deoxyuridine (BrdU) for
24 h as described44. The cells were placed in a Chamlide TC-A live-cell imaging
chamber that was mounted on the stage of a Leica DM IRBE wideﬁeld microscope
stand (Leica, Wetzlar, Germany) integrated with a pulsed nitrogen laser (Micro-
point Ablation Laser System; Photonic Instruments, Inc., Belfast, Ireland). The
pulsed nitrogen laser (16 Hz, 364 nm) was directly coupled to the epiﬂuorescence
path of the microscope and focused through a Leica 40 × HCX PLAN APO
1.25–0.75 oil-immersion objective. The growth medium was replaced by CO2-
independent Leibovitz’s L15 medium supplemented with 10% FCS and
penicillin–streptomycin and cells were kept at 37 °C. The laser output power was
set to 75 to generate strictly localized sub-nuclear DNA damage. Cell were micro-
irradiatied (two iterations per pixel) within 35 min using Andor IQ software.
Following micro-irradiation, cells were incubated for the indicated time-points at
37 °C in Leibovitz’s L15 and subsequently ﬁxed with 4% formaldehyde before
immunostaining.
Immunoﬂuorescence. BRCA1, γH2AX, and GFP staining: Cells were seeded on
coverslips in 24 well plates, at a density of 2 × 104 cells/mL. For BRCA1 staining,
soluble proteins were pre-extracted with 0.2% Triton X-100 for 1 minute at room
temperature. Cells were then ﬁxed in 4% PFA and permeabilized with 0.2% Triton
X-100. After blocking in 10% FCS in PBS for 1 h at room temperature, cells were
incubated with primary antibodies overnight and with secondary AlexaFluor
antibodies for 1 h at room temperature. DNA was stained with DAPI.
RAD51 and FANCD2 staining: Cells were washed with PBS containing 0.1%
Tween20 (PBST), ﬁxed 20 min with 2% paraformaldehyde (w/v) in PBS and
blocked in PBST containing 5% bovine serum albumin (BSA) (w/v). Primary
antibody incubation with anti-Rad51 (H-92) antibody (Santa Cruz, sc-8349)
diluted 1:100 or anti-FANCD2 antibody (Santa Cruz, sc-20022) diluted 1:100 in 5%
BSA PBST was performed at 4 °C overnight. After washing with PBST, cells were
incubated with AlexaFluor 488-conjugated secondary antibody (Molecular Probes,
A11034) diluted 1:1000 in 5% BSA PBST and counterstained with DAPI (2 μg/mL).
After washing in PBST the cells were mounted using Vectashield (Vector Labs).
Labeling of laser micro-irradiated cells: Cells were pre-extracted with 0.25%
Triton-X-100 (Serva, Heidelberg, Germany) in cytoskeletal (CSK) buffer (10 mM
Hepes-KOH, 300 mM Sucrose, 100 mM NaCl, 3 mMMgCl2, pH 7.4) on ice for 1 or
2 min and subsequently ﬁxed with 2% formaldehyde in PBS for 20 min at room
temperature. Cells were blocked for 15 min in PBS with 0.5% BSA and 0.15% glycin
(PBS+). Antibody steps and washes were in PBS+. The primary antibodies were
incubated overnight at 4 °C. Detection was done using goat anti-mouse or goat
anti-rabbit Ig coupled to Alexa 488, 546 or 647 (1:1000; Invitrogen Molecular
probes). Samples were incubated with 0.1 μg/mL DAPI and mounted in
Polymount.
Microscopy of immunoﬂuorescence. γH2AX imaging: Images were taken with a
Leica DMI 6000B microscope with an HBO lamp with a 100-W mercury short arc
UV-bulb light source and six ﬁlter cubes, with only three cubes necessary to
produce excitations at wavelengths of 360, 488, and 555 nM. Images were captured
at each wavelength sequentially with a Plan apochromat HCX 100 × /1.4 oil
objective at a resolution of 1392 × 1040 pixels.
BRCA1 imaging: Images were captured on a AxioImager M2, with three lasers
giving excitation at 360, 555 and 488 nM wavelengths. Images at each wavelength
were collected sequentially at a resolution of approximately 1024 × 1024 pixels,
with a Plan apochromat 100 × /1.4 oil objective.
RAD51 and FANCD2 imaging: Images were captured on a FluoView 1000
confocal microscope (Olympus) through a 100 × UPlanSApo/1.4 Oil objective.
Images were collected sequentially at each wavelength (405 nm and 488 nm) at the
same resolution as above.
Imaging of laser micro-irradiated cells: Images of ﬁxed samples were acquired
on a Zeiss AxioImager M2 or D2 wideﬁeld ﬂuorescence microscope equipped with
40 × , 63 × and 100 × PLAN APO (1.4 NA) oil-immersion objectives (Zeiss) and an
HXP 120 metal-halide lamp used for excitation. Fluorescent probes were detected
using the following ﬁlters: DAPI (excitation ﬁlter: 350/50 nm, dichroic mirror: 400
nm, emission ﬁlter: 460/50 nm), GFP/Alexa 488 (excitation ﬁlter: 470/40 nm,
dichroic mirror: 495 nm, emission ﬁlter: 525/50 nm), mCherry (excitation ﬁlter:
560/40 nm, dichroic mirror: 585 nm, emission ﬁlter: 630/75 nm), Alexa 555
(excitation ﬁlter: 545/25 nm, dichroic mirror: 565 nm, emission ﬁlter: 605/70 nm),
Alexa 647 (excitation ﬁlter: 640/30 nm, dichroic mirror: 660 nm, emission ﬁlter:
690/50 nm). Images were recorded using ZEN 2012 software.
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Quantiﬁcation and analysis of immunoﬂuorescence. BRCA1 and γH2AX ana-
lysis: Quantiﬁcation of foci (number and intensity) was performed using Cell
Proﬁler software.
RAD51 and FANCD2 foci analysis: Quantiﬁcation of Rad51 foci was performed
in ImageJ using a macro developed by Dr. Richard Butler at the Gurdon Institute
Imaging Facility (University of Cambridge), which is essentially a version of the
FindFoci plugin speciﬁcally optimized for Rad51 and FANCD2 foci quantiﬁcation
and the immunoﬂuorescence conditions detailed above.
Local irradiated areas: Images recorded after micro-irradiation of cells were
analyzed using ImageJ software. The average pixel intensity of laser tracks was
measured within the locally irradiated area (Idamage), in the nucleoplasm outside the
locally irradiated area (Inucleoplasm) and in a region not containing cells in the same
ﬁeld of view (Ibackground). The relative level of accumulation expressed relative to
the protein level in the nucleoplasm was calculated as follows: ((Idamage -
Ibackground)/(Inucleoplasm - Ibackground) – 1) for GFP signals and ((Idamage - Ibackground) -
(Inucleoplasm - Ibackground) – 1) for γH2AX signals. The average reﬂects the
quantiﬁcation of between 50–150 cells from 2–4 independent experiments.
Immunoblotting and antibodies. Cell extracts were prepared in RIPA lysis buffer
(NEB) supplemented with protease inhibitors (Sigma) and phosphatase inhibitors
(Sigma, NEB). Immunoblots were performed using standard procedures. Protein
samples were separated by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) (4–12% gradient gels; Invitrogen) and subsequently trans-
ferred onto nitrocellulose membranes. Details of primary antibodies used for
western blotting (WB) and immunoﬂuorescence (IF) are described in Supple-
mentary Table 1. Secondary antibodies were used at 1:5000 (HRP-conjugated goat
anti-mouse, rabbit or goat IgG from Jackson Immunochemicals) for WB and 1:600
or 1:1000 for IF (AlexaFluorophores).
H2A immunoprecipitation. HAP1 cells were transfected in 15 cm dishes with
FLAG-H2A constructs using X-fect transfection reagent (Clontech) and 40 h later
treated with mitomycin C for 4 h. Cell extracts were prepared in nuclear/chromatin
extraction HEPES buffer (HEPES 20 mM pH 7.9, NaCl 420 mM, glycerol 25%,
EGTA 1mM, EDTA 1mM, DTT 0.1 mM) supplemented with NaF 50 mM,
Na3VO4 1 mM, PMSF 1mM, NEM 20mM, protease inhibitor cocktail (Sigma-
Aldrich) and Benzonase endonuclease 25 U/mL (Merck-Millipore). After lysis,
extracts were sonicated and protein was quantiﬁed by Bradford. One milligram of
lysate was used for immunoprecipitation after dialysis with HEPES buffer to a ﬁnal
salt concentration of 150 mM NaCl and then incubated with FLAG M2 Magnetic
Beads (Sigma-Aldrich) overnight at 4 oC. Beads were washed in wash buffer
(HEPES 50 mM, NaCl 150 mM, EDTA 5mM, NP-40 substitute 0.2% three times
and bound proteins were eluted in 2 × Laemmli Sample Buffer for 20 min with
gentle agitation. Eluates were loaded on SDS–PAGE gels for western blot.
RPA70 immunoprecipitation. To test whether RPA70 is de-ubiquitylated in an
USP48-dependent manner, we co-expressed HA-ubiquitin in either GFP-
expressing or GFP-RPA70-expressing U2OS cells (kind gift from John Rouse at
University of Dundee), transfected with pre-design DsiRNAs targeting USP48
(from Integrated DNA Technologies) using Lipofectamine RNAiMAX according to
the manufacturers’ instructions. Seventy-two hours post-tranfection cells were
treated or mock-treated with camptothecin (TOP1 inhibitor) 1 μM for 1 h. Next,
we prepared cell extracts and assessed GFP immunoprecipitates for HA-ubiquitin
and FK2 staining by immunoblotting as described in Schmidt et al.26 Brieﬂy, U2OS
cells expressing GFP or RPA70-GFP were transfected in 10 cm dishes with
negative-control or USP48-targeting DsiRNAs using Lipofectamine RNAiMAX
(Thermo Fisher Scientiﬁc) the night before. The following day cells were trans-
fected with a mammalian expression plasmid encoding 3 × HA-Ubiquitin using
TransIT-LT1 transfection reagent (Mirus Bio LLC), and 48 h later treated with
camptothecin plus 10 μM MG132 proteasome inhibitor for 1 h. Cell extracts were
prepared by scraping cells from PBS-washed plates into ice-cold lysis buffer (20
mM Tris-HCl pH 7.5, 40 mM NaCl, 2 mM MgCl2, 10% glycerol, and 0.5% NP-40)
containing EDTA-free protease inhibitor cocktail (Roche) and benzonase
(10 µl/mL lysis buffer, Novagen 70664-3). After increasing the salt concentration to
~250 mM NaCl, extracts were rotated for 10–15 min at room temperature, sub-
sequently diluted 1:2 with lysis buffer (without benzonase) and the extracts cleared
by centrifugation at 16,000 × g for 45 min at 4 °C. Immunoprecipitation reactions
were rotated overnight at 4 °C using GFP-Trap-A beads (ChromoTek, 10 µl per mg
protein) followed by ﬁve washes with immunoprecipitation buffer (lysis buffer
without benzonase containing a ﬁnal concentration of ~250 mM NaCl). Proteins
were eluted from the GFP-Trap-A beads in a 5-10-min incubation step at 95 °C in
1.5 × SDS sample buffer and loaded on SDS–PAGE gels for western blot.
TLR assay. . A minimum of 10,000 doubly-transfected (IFP+ and BFP+) cells
were scored for each condition in four independent experiments, three of which
performed in duplicate using either of two different DsiRNAs targeting USP48 or
FANCC26. Analyses were conducted using FlowJo (TreeStar). For each DsiRNA
treatment, results were normalized (including the negative-control DsiRNA) to
cells treated with RNAiMAX only, resulting in relative homologous recombination
(HR) and mutagenic end-joining (mutEJ) percentages for each DsiRNA treatment.
Finally, the HR values for each condition were normalized to the total amount of
cells in S and G2 phases obtained by ﬂow-cytomtery analysis of a subset of DAPI-
stained cells transfected only with DsiRNAs and grown in parallel at the same cell
density.
RPA70-GFP chromatinization. Cells were mock-treated or treated for 1 h with
1 μM camptothecin to induce replication fork collapse, and then processed as
described in detail in Forment and Jackson45. RPA70-GFP+ cells were co-stained
with DAPI and analyzed by ﬂow-cytometry using a BD LSRFortessa™ cell analyzer
(BD Biosciences).
Metaphase spreads. Cells were seeded in 10 cm dishes and treated with MMC for
the indicated times. Colcemid (KaryoMAXTM, Gibco, Thermo Fisher Scientiﬁc)
was added at a ﬁnal concentration of 500 ng/mL 3 h before harvesting. Cells were
trypsinized and incubated in KCl at 0.075M (KaryoMAXTM, Gibco, Thermo
Fisher Scientiﬁc) for 6 min. After centrifugation, cells were resuspended in ﬁxation
solution (methanol:acetic acid at 3:1) and incubated for 15 min at room tem-
perature. Centrifugation and re-suspension in fresh ﬁxation solution was repeated
two times. Metaphase spreads, slide preparation and measurement of chromosomal
aberrations was performed at Karyologic Inc (North Carolina, USA). All analysis
was performed in a blinded manner. Fifty metaphases were scored for each con-
dition, providing a total count of the overall chromosome counts, and the total of
the different types of aberrations (chromatid gaps, chromosome gaps, chromatid
breaks, chromosome breaks, double minutes, tri-radial, quadri-radial, complex re-
arrangement, pulverized, and polyploid).
Genome-wide insertional mutagenesis. Gene-trap virus was produced in
HEK293T using Lipofectamine 2000 Transfection reagent (Invitrogen, Thermo
Fisher Scientiﬁc)11. ΔFANCA, ΔFANCC, ΔFANCG, ΔFANCI, and ΔFANCD2
HAP1 cells were transduced with concentrated retrovirus containing the gene-trap
cassette11. After integration of the GFP-expressing gene-trap cassette, cells were
analyzed by ﬂow-cytometry to measure efﬁciency of infection and populations with
more than 70% GFP-expressing cells were used for treatment with MMC. The
control non-selected WT-HAP1 population was generated in Blomen et al.14. One-
hundred million cells from the mutagenized pools were seeded in 15 cm dishes at a
density of 6 million cells per dish. The following day, MMC was added at a
concentration that selectively killed FA-deﬁcient cells, leaving only around 5–10%
of cells surviving (46 nM for ΔFANCA, ΔFANCC, and ΔFANCG, 40 nM for
ΔFANCI and ΔFANCD2). Cells were left to grow for 10 days after which cells were
trypsinized and frozen at -80 °C. For preparation of the gene-trapped DNA
libraries, genomic DNA was extracted from 30 million cells using the QIAamp
DNA mini kit (Qiagen), subjected to digestion with MseI (NEB) and NlaIII
enzymes (NEB) and subsequently ligated by T4 DNA ligase (NEB). Digested and
ligated fragments were used as templates for inverse PCR with primers targeting
the LTR regions of the gene-trap cassette. After ampliﬁcation and puriﬁcation of
the fragments, the DNA sample was prepared for next generation sequencing
(Illumina HiSeq 2000,50 base pair single-read) by the CeMM Biomedical
Sequencing Facility (BSF). For the control non-selected WT-HAP1 sample, sam-
ples from Blomen et al.14 were used.
Statistical analysis. Gene-trap screen: Bioinformatics analysis of the next gen-
eration sequencing data was done in R as described18. Insertions were considered
mutagenic or disruptive to the gene if they occurred within exons irrespective of
their orientation to the corresponding gene or if they were located within introns in
sense orientation. Insertions in antisense direction in respect to the gene orienta-
tion were considered silent. All mutagenic insertions were summarized indepen-
dently for each gene. For each gene a one-sided Fisher’s exact-test was applied to
estimate a signiﬁcant enrichment of insertions over an unselected control data set.
Immunoﬂuorescence analysis: Statistical analysis of the immunoﬂuorescence
data was performed using Prism software. We performed Student T-test analysis to
determine statistical signiﬁcances between independent samples, this test requires
the assumption of a normal distribution of the groups. When it is not possible to
assume a normal distribution, we have performed the Mann–Whitney test.
Metaphase spreads analysis: Statistical analysis was performed using Prism
software. We performed a Mann–Whitney test. The signiﬁcance was indicated as:
****= p < 0.0001, ***= p < 0.001, **= p < 0.01, *= p < 0.05, N.S.= not signiﬁcant.
Network analysis. Background network construction: Network analysis methods
were employed to explore the functional context of the genes identiﬁed in the FA
screens (individual, all combined, and those unique to the screens not found in
WT). The background interactome used was that compiled by Menche et al.15 and
contains physical protein–protein interactions that were manually curated from
seven different databases, including regulatory interactions (TRANSFAC), Yeast
two-hybrid screens (IntAct, MINT), literature curated interactions (IntAct, MINT,
BIOGRID, HPRD), metabolic enzyme-coupled interactions (KEGG, BIGG), pro-
tein complexes (CORUM), kinase network (PhosphositePlus), and signaling
interactions46. A gene list from the FA screens (individual, all combined and those
unique to the screens not found in WT) was used to seed the network.
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Network propagation: To identify the local interactome neighborhoods of the
genes identiﬁed in the FA screen, we implemented the network propagation
method previously published15. Brieﬂy, the method simulates how heat would
diffuse, with loss, through the network by traversing the edges, starting from an
initially hot set of ‘‘seed’’ nodes. At each step, one unit of heat is added to the seed
nodes and is then spread to its neighbors. A constant fraction of heat is then
removed from each node, so that total heat is conserved in the system. The amount
of heat per node eventually converges to a stable value, which can then be used as a
measure of its integrated distance to the set of seed nodes. For example, a node
connected to several seed nodes would have a higher ﬁnal heat value than a node
that is located far from the seeds.
Identify network neighborhood of seed genes and clustering: The network
propagation method described above ﬁnds genes, which are close to the set of seed
genes in network space. We sort the genes in the network by their network
propagation score, and extract genes in the top N (N= 1000 here) of the sorted list
to deﬁne the network neighborhood. This results in a subgraph, which we cluster
into groups of highly interconnected genes, using a modularity maximization
clustering algorithm17. Functional enrichment analysis of the genes in each cluster
was performed using the ToppFun function of ToppGene47 and the ORA function
as published48.
Data availability. All data generated or analyzed during this study is included in
this published article and its Supplementary Information or from the authors upon
reasonable request.
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